Kindred Biosciences, Inc.
(NASDAQ CM: KIN)
Rigrodsky Law, P.A. is investigating Kindred Biosciences, Inc. (“Kindred”) regarding possible breaches of fiduciary duties and other violations of law related to Kindred’s agreement to be acquired by Elanco Animal Health Incorporated and Knight Merger Sub, Inc. Under the terms of the agreement, Kindred’s shareholders will receive $9.25 in cash per share.